Wall Street brokerages predict that ABIOMED, Inc. (NASDAQ:ABMD) will post earnings of $0.93 per share for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for ABIOMED’s earnings, with estimates ranging from $0.86 to $1.01. ABIOMED reported earnings of $0.81 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 14.8%. The firm is expected to issue its next earnings results on Thursday, November 7th.

According to Zacks, analysts expect that ABIOMED will report full year earnings of $4.29 per share for the current fiscal year, with EPS estimates ranging from $4.19 to $4.43. For the next fiscal year, analysts expect that the firm will post earnings of $5.39 per share, with EPS estimates ranging from $4.86 to $6.24. Zacks’ EPS averages are a mean average based on a survey of research firms that cover ABIOMED.

ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings results on Thursday, August 1st. The medical equipment provider reported $1.00 EPS for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.01. ABIOMED had a return on equity of 19.84% and a net margin of 32.35%. The business had revenue of $207.70 million during the quarter, compared to the consensus estimate of $210.96 million. During the same quarter in the previous year, the firm earned $1.95 earnings per share. ABIOMED’s revenue for the quarter was up 15.4% compared to the same quarter last year.

ABMD has been the subject of several analyst reports. BTIG Research cut shares of ABIOMED from a “buy” rating to a “neutral” rating in a research report on Thursday, August 1st. Morgan Stanley lowered shares of ABIOMED from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $325.00 to $215.00 in a research report on Thursday, August 1st. William Blair restated a “buy” rating on shares of ABIOMED in a research report on Friday, August 2nd. Guggenheim downgraded shares of ABIOMED from a “buy” rating to a “neutral” rating in a research report on Friday, August 2nd. Finally, BidaskClub cut ABIOMED from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 31st. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $316.50.

ABIOMED stock traded down $0.75 during trading hours on Friday, reaching $191.07. 484,606 shares of the stock were exchanged, compared to its average volume of 634,107. ABIOMED has a twelve month low of $180.00 and a twelve month high of $459.75. The company has a market cap of $8.70 billion, a P/E ratio of 53.08, a price-to-earnings-growth ratio of 1.65 and a beta of 0.45. The stock has a 50 day moving average of $207.00 and a two-hundred day moving average of $261.59.

In other ABIOMED news, COO David M. Weber sold 8,095 shares of ABIOMED stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $206.26, for a total value of $1,669,674.70. Following the transaction, the chief operating officer now owns 132,913 shares in the company, valued at $27,414,635.38. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 3.40% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. lifted its stake in ABIOMED by 9.4% in the second quarter. BlackRock Inc. now owns 3,389,676 shares of the medical equipment provider’s stock valued at $882,977,000 after buying an additional 290,358 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of ABIOMED by 18.0% during the 2nd quarter. Renaissance Technologies LLC now owns 2,431,723 shares of the medical equipment provider’s stock worth $633,440,000 after buying an additional 370,800 shares in the last quarter. Baillie Gifford & Co. raised its holdings in shares of ABIOMED by 105.2% during the 2nd quarter. Baillie Gifford & Co. now owns 2,219,136 shares of the medical equipment provider’s stock worth $578,063,000 after buying an additional 1,137,705 shares in the last quarter. Brown Capital Management LLC lifted its position in shares of ABIOMED by 10.2% during the 2nd quarter. Brown Capital Management LLC now owns 1,358,476 shares of the medical equipment provider’s stock worth $353,869,000 after buying an additional 125,857 shares during the last quarter. Finally, William Blair Investment Management LLC lifted its position in shares of ABIOMED by 338.3% during the 2nd quarter. William Blair Investment Management LLC now owns 815,524 shares of the medical equipment provider’s stock worth $212,436,000 after buying an additional 629,455 shares during the last quarter. Institutional investors own 91.53% of the company’s stock.

About ABIOMED

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Recommended Story: Do equity income investments outperform growth and income investments?

Get a free copy of the Zacks research report on ABIOMED (ABMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.